Skip to content

EEG Objectification in Neuropsychiatry

EEG Objectification in Neuropsychiatry

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01476228
Enrollment
100
Registered
2011-11-22
Start date
2011-11-30
Completion date
2015-12-31
Last updated
2011-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality Disorder, Depression, Neurodegeneration, Alzheimer's Disease, Epilepsy

Brief summary

The main objective of the study is to evaluate the use of EEG in the management and follow-up of neuropsychiatric disorders. Secondary objectives are therefore better understanding of the pathological activations in neural network during neuropsychiatric disorders, their clinical evolution and response to therapies.

Detailed description

Patients are having EEG recordings as a routine part of their clinical evaluation and diagnosis. EEG recording is harmless, has no side effects, any radiation or any mechanical or electrical influence. It is of short duration and may be done in the EEG institute or the patient's room.

Interventions

EEG recording

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* diagnosis of the investigated neuropsychiatric disease

Exclusion criteria

* Other co-existing neuropsychiatric conditions * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
percentage of fitting (0-100%) of EEG pattern to a previously identified electrophysiological key1 yearThe study will decode an EEG-based key (or electrophysiological pattern) for specific effect (such as the use of anti-epileptic agent or a certain condition) by comparing EEG before and after the use of this agent. For each patient the statistical fitting of the recorded EEG to the key will be evaluated by percentage (0-100%), describing fitting of the individual patient's EEG to the identified key.

Countries

Israel

Contacts

Primary Contactshahar arzy, MD PhD
shahar.arzy@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026